A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

被引：16

作者：

Aboudalle, Iman ^{[1
]}

Konopleva, Marina Y. ^{[2
]}

Kadia, Tapan M. ^{[3
]}

Naqvi, Kiran ^{[4
]}

Vaughan, Kenneth ^{[4
]}

Kurt, Mehmet ^{[5
]}

Cavazos, Antonio ^{[4
]}

Pierce, Sherry A. ^{[4
]}

Takahashi, Koichi ^{[4
]}

Masarova, Lucia ^{[4
]}

Yilmaz, Musa E. ^{[4
]}

Jabbour, Elias ^{[4
]}

Garcia-Manero, Guillermo ^{[4
]}

Kornblau, Steven M. ^{[6
]}

Ravandi, Farhad ^{[4
]}

Cortes, Jorge ^{[2
]}

Kantarjian, Hagop M. ^{[3
]}

DiNardo, Courtney D. ^{[4
]}

机构：

[1] Amer Univ Beirut, Hemtol Oncol Div, Beirut, Lebanon

[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[3] MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1182/blood-2019-121780

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

176

引用

页数：5